Schedule 13G Filing for Traws Pharma, Inc. by Squadron Master Fund LP and Others

Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have filed a Schedule 13G with the SEC regarding their ownership in Traws Pharma, Inc. The filing indicates that Squadron Master Fund LP owns 5.3% of the common stock, while Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank each own 6.0%. The shares are held through various funds managed by Squadron Capital Management, LLC, which is an investment adviser registered with the SEC. The filing also includes certifications that the securities were not acquired for the purpose of influencing the control of the issuer. The event date requiring this filing is September 12, 2025.